medigraphic.com

2007, Number 5

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2007; 45 (5)

Acute Cystitis in Women with Type 2 Diabetes. Three Antimicrobial Schemes to Treat

López-Carmona JM, Salazar-López MA, Rodríguez-Moctezuma JR, López-Delgado ME, Manrique-Lizárraga JM

Language: Spanish
References: 31
Page: 503-512
PDF size: 158.78 Kb.


ABSTRACT

Objective: To compare the effectiveness and secondary effects of trimethoprim-sulfamethoxazole (TMP-SMX), ciprofloxacin, and nitrofurantoin in women with type 2 diabetes mellitus (DM2) and acute community-acquired cystitis.
Methods: A randomized single blind clinical trial was conducted in the family medicine clinic No. 91 of Instituto Mexicano del Seguro Social in Coacalco, Mexico. The study included women with DM2 and acute cystitis who were randomly allocated to one of the following schemes: TMP-SMX (160/800 mg every 12 h), ciprofloxacin (500 mg every 12 h) or nitrofurantoin (100 mg every 6 h) for 10 days.
Results: Sixty-one patients fulfilled the inclusion criteria. Bacteriologic eradication at the end of the treatment was observed in 18/23 (78 %) of patients treated with ciprofloxacin; 14/18 (78%) of patients treated with nitrofurantoin; and 9/20 (45 %) of patients treated with TMP-SMX (p = .036). The difference between nitrofurantoin and TMP-SMX, as well as between ciprofloxacin with TMP-SMX, was 33 % for both (95 % confidence interval = 4 %, 62 %, and 5 %, 61 % respectively). The most frequently isolated bacterium was Escherichia coli (75 %), The in vitro resistance rate to TMP-SMX was 76 %, to ciprofloxacin 17 % and to nitrofurantoin 13 % (p = 0.05). The main adverse effects were slight to moderate headache, nausea, and pyrosis in the three groups.
Conclusions: ciprofloxacin and nitrofurantoin were more effective than TMP-SMX for the treatment of community-acquired acute cystitis in Mexican women with DM2. This is probably due to differences in the resistance rates and is probably not specific for diabetic patients; All three antimicrobials were safe.


REFERENCES

  1. Hoepelman IM. Urinary tract infection in patients with diabetes mellitus. Int J Antimicrob Agents 1994;4:113-116.

  2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113(1A):5S-13S.

  3. Zárate A. Diabetes mellitus in Mexico. Diabetes Care 1991;14(7):672-675.

  4. Villarreal-Ríos E, Salinas-Martínez AM, Medina-Jáuregui A, Garza-Elizondo ME, Núñez-Rocha G, Chuy-Díaz ER. The cost of diabetes mellitus and its impact on health spending in Mexico. Arch Med Res 2000;31:511-514.

  5. Aguilar-Salinas CA, Velásquez-Monroy O, Gómez-Pérez FJ, et al. Characteristics of patients with type 2 diabetes in Mexico. Diabetes Care 2003; 26:2021-2026.

  6. Dirección General de Información y Evaluación del Desempeño, Secretaría de Salud. Estadísticas de mortalidad en México: muertes registradas en el año 2001. Salud Publica Mex 2003;44:565-576.

  7. Patterson JE, Andriole VT. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am 1997;11(3):735-750.

  8. Geerlings SE, Stolk RP, Camps MJL, Netten PM, Collet TJ, Hoepelman AIM. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000;23(12):1737-1741.

  9. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med 2002;113(1A):81S-84S.

  10. Geerlings SE, Meiland R, Van Lith EC, Brouwer EC, Gaastra W, Hoepelman AIM. Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: more in diabetic women than in control subjects. Diabetes Care 2002;25(8):1405-1409.

  11. Geerlings SE, Meiland R, Hoepelman AIM. Pathogenesis of bacteriuria in women with diabetes mellitus. Int J Antimicrob Agents 2002;19:539-545.

  12. Ronald A, Ludwig E. Urinary tract infections in adults with diabetes. Int J Antimicrob Agents 2001;17:287-292.

  13. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 2002;113(1A):14S-18S.

  14. Warren JW, Abrutyn E, Heberl JR, Johnson JR, Schaeffer AH, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999;29:745-758.

  15. Meiland R, Geerlings SE, Hoepelman AIM. Management of bacterial urinary tract infections in adult patients with diabetes mellitus. Drugs 2002; 62(13):1859-1868.

  16. Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. Am J Med 2002;113(1A): 35S-44S.

  17. Hoepelman AIM, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 2003;22(S2):35-43.

  18. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 2001;135(1):41-50.

  19. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999;281(8):736-738.

  20. Rivas-Espinoza V, Ortiz MA. Resistencia antimicrobiana de Escherichia coli uropatógena aislada de pacientes comunitarios. Rev Mex Patol Clin 1998;45(4):201-205.

  21. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA:NCCLS, 1998.

  22. Lye WC, Chan RTK, Lee EJC, Kumarasinghe G. Urinary tract infections in patients with diabetes mellitus. J Infect 1992;24:169-174.

  23. Bonadio M, Meini M, Gigli C, Longo B, Vigna A. Urinary tract infection in diabetic patients. Urol Int 1999;63(4):215-219.

  24. González-Ortiz M, Martínez-Abundis E, Cardona-Muñoz EG. Lomefloxacina versus trimetoprim con sulfametoxazole en la infección de vías urinarias del anciano con diabetes mellitus. Med Intern Mex 1997;13(4):169-172.

  25. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO-SENS Project. J Antimicrob Chemother 2003;51:69-76.

  26. Huovinen P, Sundström L, Swedberg G, Sköld O. Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother 1995;39(2):279-289.

  27. Allais JM, Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections. Antimicrob Agents Chemother 1988;32(9):1327-1330.

  28. Grubbs NC, Schultz HJ, Henry NK, Ilstrup DM, Muller SM, Wilson WR. Ciprofloxacin versus trimethoprim-sulfamethoxazole: treatment of community-acquired urinary tract infections in a prospective, controlled, double-blind comparison. Mayo Clin Proc 1992;67:1163-1168.

  29. Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother 1999;43(Suppl A):67-75.

  30. McCarty JM, Richard G, Huck W, et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim-sulfamethoxazole for the treatment of acute urinary tract infection in women. Am J Med 1999;106:292-299.

  31. Meiland R, Geerlings SE, De Neeling AJ, Hoepelman AIM. Diabetes mellitus in itself is not a risk factor for antibiotic resistance in Escherichia coli isolated from patients with bacteriuria. Diabet Med 2004;21:1032-1034.




2020     |     www.medigraphic.com